Diabetic Neuropathy Market

Diabetic Neuropathy Market Study by Peripheral Neuropathy, Autonomic Neuropathy, and Proximal Neuropathy from 2023 to 2033

Analysis of Diabetic Neuropathy Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more

Diabetic Neuropathy Market Outlook (2023 to 2033)

The global diabetic neuropathy market is valued at US$ 4.2 billion in 2023 and is estimated to reach US$ 8 billion by the end of 2033. Global demand for diabetic neuropathy is forecasted to increase steadily at 6.6% CAGR over the next ten years.

Diabetes has the potential to damage an individual’s nerves and this damage caused is termed diabetic neuropathy and mostly affects the feet and legs. Diabetic neuropathy symptoms can be mild for some while severe for others causing numbness, issues with controlling the heart rate, etc., and can even prove fatal in certain cases if not treated with proper attention and care.

The world has witnessed a notable increase in the incidence of chronic diseases around the world and this trend is projected to significantly boost demand for diabetic neuropathy treatment in the future since cases of diabetes are rising rapidly around the world. Growing focus on health, rising investments in medical research, increasing healthcare expenditure, growing awareness regarding diabetic neuropathy, poor lifestyle habits, high incidence of obesity, and an expanding aging population are key aspects that could promulgate the demand for diabetic nerve treatment products and therapies across the forecast period.

Rising availability of over-the-counter diabetic neuropathy treatment medications is anticipated to create lucrative growth opportunities for established as well as upcoming diabetic neuropathy drug manufacturers in the future. Homeopathic diabetic neuropathy, multivitamins for diabetic neuropathy, and diabetic neuropathy holistic treatment are some of the popular treatments available in the marketplace at present.

Increasing advancements in research and development are predicted to bolster the demand for advanced treatment therapies and products such as infrared therapy for diabetic neuropathy going forward.

On the flip side, the high availability of alternative therapies for diabetic neuropathy treatment and the high costs of diabetic neuropathy therapeutics and drugs are extrapolated to thwart overall market development through 2033.

Report Attributes

Details

Market Size (2023)

US$ 4.2 Billion

Projected Market Value (2033F)

US$ 8 Billion

Global Market Growth Rate (2023 to 2033)

6.6% CAGR

Market Share Peripheral Neuropathy (2022)

>50%

Proximal Neuropathy Segment Growth Rate (2023 to 2033)

5.4% CAGR

Peripheral Neuropathy Segment Growth Rate (2023 to 2033)

5.8% CAGR

Key Companies Profiled

  • NeuroMetrix Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson (Janssen Global Services LLC)
  • Lupin Limited
  • Astellas Pharma Inc.
  • Depomed Inc.
  • Arbor Pharmaceuticals LLC
  • Boehringer Ingelheim GmbH
  • Eli Lilly and Company
  • Glenmark Pharmaceuticals Ltd.
  • Pfizer Inc.

Don't Need a Global Report?

save 40%! on Country & Region specific reports

Which Factors are Altering Demand for Neuropathic Pain Treatments?

“Growing Prevalence of Diabetes across the World”

Diabetes has become a renowned worldwide phenomenon that affects millions of people. Adoption of sedentary lifestyles and poor eating habits are at the helm of the rising incidence of diabetes around the world and are expected to bolster demand for novel diabetic neuropathy treatment formulations in the future. The increasing geriatric population across the world is also slated to contribute to the growing prevalence of diabetes and diabetic neuropathy on a global level going forward.

  • As per the statistics listed on the International Diabetes Federation (IDF) website, nearly 643 million people are anticipated to be suffering from diabetes by the end of 2030. Nearly 90% of these people are expected to be living with Type 2 diabetes.

“Increasing Investments in R&D on Diabetes Treatment”

Diabetes has become a public health issue, which has led to an increased focus on the research and development of treatments for the condition from the public as well as private sectors. Supportive government initiatives to promote the development of diabetic nerve treatment products are anticipated to uplift market growth over the coming years. Moreover, increasing investments in healthcare R&D by prime biopharmaceutical companies and private sector organizations are also projected to bolster market evolution in the future.

  • A new study published by researchers at the Salk Institute in Nature (a leading science journal) on 25th January 2023 revealed that low levels of amino acid serine increased the risk of developing peripheral neuropathy for diabetic mice. These new findings could be used to explore the use of serine supplementation to alleviate the symptoms of neuropathy symptoms and possibly take us one step closer to developing a possible cure.

Diabetic neuropathy market growth forecast by Fact.MR

How are New Companies Transforming Diabetic Neuropathy Care?

“Start-ups Focusing on Development of Novel Treatment Products & Services”

Aspiring diabetic neuropathy treatment companies are focusing on developing novel products that provide diabetic foot pain relief and better help for diabetic neuropathy to revolutionize the marketplace and establish a presence for themselves on a global level.

  • Healables, a start-up based in Israel is revolutionizing pain management and chronic pain relief by using a combination of artificial intelligence and embedded electrodes. The electrodes are embedded in an elasticized sleeve that gently vibrates and stimulates cells into self-repair. The device is undergoing trials with diabetic neuropathy patients in the United Kingdom at Derby Teaching Hospitals NHS Foundation Trust.

New entrants in the industry are also focusing on bagging new funds to finance their research and expansion efforts that help them strengthen their stance in the global competitive landscape.

  • In August 2022, Yostra Labs, an India-based medtech start-up announced that it had raised US$ 484,164 in a seed funding round that was led by Villgro Innovations Foundation, Indian Angel Network, and other investors. The company has a specialized portfolio of products for the management and diagnosis of peripheral neuropathy. The company was expected to use the raised capital to expand its workforce and marketing teams.

This latest diabetic neuropathy market research report by Fact.MR, a market research and competitive intelligence provider, proffers a comprehensive assessment of how new developments by start-ups are altering product standards, pricing trends, local supply, and safety regulations on a global level.

More Insights, Lesser Cost (-50% off)

Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR

Country-wise Insights

Will the United States be a Profitable Market for Diabetic Neuropathy Drug Suppliers?

“Growing Obesity to Create Attractive Business Scope”

Obese people are at an increased risk of contracting diabetes and diabetic neuropathy, which makes the United States a highly opportune market because obesity has been increasing at an alarming pace in the country in recent years. Poor lifestyle choices, lack of exercise, consumption of processed foods, and improper nutrition are key factors leading to an increasing prevalence of obesity among the citizens of the United States and driving diabetic neuropathy market growth potential.

Increasing investments in research, the presence of developed healthcare infrastructure, the launch of novel therapeutics for diabetic foot pain relief, and an increasing number of product approvals from regulatory authorities are other prospects that promulgate demand for diabetic nerve pain treatment. Early adoption of diabetic neuropathy treatment drugs and the growing availability of advanced treatments open up new avenues of opportunity for diabetic neuropathy treatment companies in the country.

Why are Investors Focusing on Japan for Diabetic Neuropathy?

“Expanding Geriatric Population Propelling Demand for Diabetic Nerve Pain Treatment”

Japan is a highly remunerative market for established as well as upcoming diabetic neuropathy treatment companies owing to its growing senescent population that is at increased risk of suffering from diabetic foot pain and other health conditions. Increasing investments by the public and private sectors to provide better healthcare for the elderly in Japan are anticipated to bolster market growth in the future.

Diabetic neuropathy natural treatment techniques and the use of natural herbs for diabetic neuropathy are anticipated to be popular in Japan owing to the high popularity and reliance of people on ancient medical practices.

Which Countries in Europe are Lucrative Markets?

“Germany, Portugal, & Ireland to Be Prime Markets in Europe”

Increasing healthcare expenditure and the rising geriatric population are the foremost prospects that are anticipated to uplift diabetic neuropathy treatment demand in the European region over the coming years. The rising number of people affected by diabetes and the increasing availability of novel over-the-counter diabetic neuropathy treatment medications and therapies are also anticipated to bolster market growth in European countries such as Germany, Ireland, Portugal, and the United Kingdom.

Category-wise Insights

Which Disorders Lead the Demand for Diabetic Neuropathy Treatment?

“Proximal & Peripheral Diabetic Neuropathy Generating Majority of Market Revenue”

Based on disorder, the diabetic neuropathy market is segmented into peripheral neuropathy, autonomic neuropathy, proximal neuropathy, and focal neuropathy.

Treatment of peripheral neuropathy is currently limited to pain management and increasing investments in research are projected to bolster the demand for proper treatment through the regeneration of nerves over the coming years. Peripheral neuropathy accounted for more than half of the global market share in 2022 and is poised to register an approximate CAGR of 5.8% over the next ten years.

Meanwhile, growing cases of people suffering from type 2 diabetes are projected to bolster demand for proximal diabetic neuropathy formulations since it is most common in people with type 2 diabetes. Proximal neuropathy is projected to account for nearly 1/4 of the global market share by the end of 2033.

Competitive Landscape :

Leading diabetic neuropathy treatment providers are focusing on hastening their research and development process to launch novel drug formulations and therapies to provide diabetic nerve pain relief.

  • In January 2023, Neuralace Medical Inc., a medical technology company announced the enrollment of the first patients for its Axon Therapy and Painful Diabetic Neuropathy (AT-PDN) study with a target of around 80 patients. The study was estimated to be conducted at five clinical sites and led by Dr. Lora Brown at TruWell Health, Florida.
  • In November 2020, Helixmith, a biotechnology company based in South Korea announced the start of a new trial for patients with diabetic neuropathy. The company was focusing on using gene therapy to treat diabetic peripheral neuropathy (DPN).

Key Segments of Diabetic Neuropathy Industry Research

  • By Disorder :

    • Peripheral Neuropathy
    • Autonomic Neuropathy
    • Proximal Neuropathy
    • Focal Neuropathy
  • By Treatment :

    • Drugs
      • Analgesic
        • Topical
          • Capsaicin
          • Others
        • Opioid
          • Morphine
          • Others
        • NSAIDs
          • Ibuprofen
          • Naproxen
          • Others
        • Antidepressants
          • TCAs
            • Amitriptyline
            • Imipramine
            • Others
          • SNRIs
            • Duloxetine
            • Others
          • SSRIs
            • Citalopram
            • Paroxetine
            • Others
        • Anticonvulsant Drugs
          • Gabapentin
          • Pregabalin
          • Topiramate
          • Others
    • Other Drugs
    • Radiotherapy
      • Transcutaneous Electrical Nerve Stimulation (TENS)
      • Others
    • Physiotherapy
  • By Distribution Channel :

    • Hospitals
    • Clinics
    • Retail Pharmacies
    • Online Pharmacies
  • By Region :

    • North America
    • Latin America
    • Europe
    • APAC
    • MEA

Table of Content

1. Market Overview

    1.1. Market Coverage / Taxonomy

    1.2. Market Definition / Scope / Limitations

2. Market Risks and Trends Assessment

    2.1. Risk Assessment

        2.1.1. COVID-19 Crisis and Impact on Demand

        2.1.2. COVID-19 Crisis and Impact on Cost

        2.1.3. COVID-19 Impact Benchmark with Previous Crisis

            2.1.3.1. Change in Demand

            2.1.3.2. Before and After COVID-19 Crisis (Projected)

            2.1.3.3. Before and After Sub-prime Crisis – 2008 (Actual)

            2.1.3.4. Change in Demand post Recovery Period (After Each Crisis)

        2.1.4. Impact on Market Value (US$ Mn)

            2.1.4.1. Likely Loss of Value in 2020

            2.1.4.2. Mid-term and Long Term Forecast

            2.1.4.3. Quarter by Quarter Demand and Recovery Assessment

        2.1.5. Anticipated Demand and Value Recovery Curve

            2.1.5.1. Likelihood of U-Shape Recovery

            2.1.5.2. Likelihood of L-Shape Recovery

        2.1.6. Recovery Period Assessment by Key Countries

        2.1.7. Recovery Assessment by Key Market Segments

        2.1.8. Action Points and Recommendation for Suppliers

    2.2. Key Trends Impacting the Market

3. Market Background and Foundation Data Points

    3.1. Global Healthcare Market Overview

    3.2. Healthcare Spending Analysis, By Key Countries

    3.3. Global Diabetes Patients Scenario, BY Key Countries

    3.4. Per Capita Spending on Diabetes, BY Key Countries

    3.5. Recent Developments in Industry

    3.6. Growth and Development Patterns in Market

    3.7. Market White Space Assessment And Opportunity Analysis

    3.8. Recent Development in Market, By Market Players

    3.9. Competitive Scenario and Trends

    3.10. Market Concentration Rate

        3.10.1. List of Emerging, Prominent and Leading Players

        3.10.2. Mergers & Acquisitions

    3.11. Scenario Forecast and in optimistic, likely, and conservative market conditions)

    3.12. Policy and Regulatory Landscape

    3.13. Macro-Economic Factors

    3.14. Forecast Factors - Relevance & Impact

    3.15. Market Dynamics

        3.15.1. Market Driving Factors and Impact Assessment

        3.15.2. Prominent Market Challenges and Impact Assessment

        3.15.3. Market Opportunities

        3.15.4. Prominent Trends in the Global Market & Their Impact Assessment

4. Key Success Factors

    4.1. Adoption / Usage Analysis

    4.2. Disorder USPs / Features

    4.3. Others (Discussed in Report)

5. Global Market Value Analysis 2018-2022 and Forecast, 2023-2033

    5.1. Historical Market Value (US$ Mn) Analysis, 2018-2022

    5.2. Current and Future Market Value (US$ Mn) Projections, 2023-2033

        5.2.1. Y-o-Y Growth Trend Analysis

        5.2.2. Absolute $ Opportunity Analysis

6. Global Market Analysis 2018-2022 and Forecast 2023-2033, By Disorder

    6.1. Introduction / Key Findings

    6.2. Historical Market Size (US$ Mn) Analysis By Disorder, 2018-2022

    6.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Disorder, 2023-2033

        6.3.1. Peripheral Neuropathy

        6.3.2. Autonomic Neuropathy

        6.3.3. Proximal Neuropathy

        6.3.4. Focal Neuropathy

    6.4. Market Attractiveness Analysis By Disorder

7. Global Market Analysis 2018-2022 and Forecast 2023-2033, By Treatment

    7.1. Introduction / Key Findings

    7.2. Historical Market Size (US$ Mn) Analysis By Treatment, 2018-2022

    7.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Treatment, 2023-2033

        7.3.1. Drug

            7.3.1.1. Analgesic

                7.3.1.1.1. Topical

                    7.3.1.1.1.1. Capsaicin

                    7.3.1.1.1.2. Others

                7.3.1.1.2. Opioids

                    7.3.1.1.2.1. Morphine

                    7.3.1.1.2.2. Others

                7.3.1.1.3. NSAIDs

                    7.3.1.1.3.1. Ibuprofen

                    7.3.1.1.3.2. Naproxen

                    7.3.1.1.3.3. Others

            7.3.1.2. Antidepressant

                7.3.1.2.1. TCAs

                    7.3.1.2.1.1. Amitriptyline

                    7.3.1.2.1.2. Imipramine

                    7.3.1.2.1.3. Others

                7.3.1.2.2. SNRIs

                    7.3.1.2.2.1. Duloxetine

                    7.3.1.2.2.2. Others

                7.3.1.2.3. SSRIs

                    7.3.1.2.3.1. Citalopram

                    7.3.1.2.3.2. Paroxetin

                    7.3.1.2.3.3. Others

            7.3.1.3. Anticonvulsants

                7.3.1.3.1. Gabapentin

                7.3.1.3.2. Pregabalin

                7.3.1.3.3. Topimarate

                7.3.1.3.4. Others

                7.3.1.3.5. Other Drugs

        7.3.2. Radiotherapy

            7.3.2.1. TENS

            7.3.2.2. Others

        7.3.3. Physiotherapy

    7.4. Market Attractiveness Analysis By Treatment

8. Global Market Analysis 2018-2022 and Forecast 2023-2033, By Distribution Channel

    8.1. Introduction / Key Findings

    8.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2018-2022

    8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2023-2033

        8.3.1. Hospitals

        8.3.2. Clinics

        8.3.3. Retail Pharmacy

        8.3.4. Online Pharmacy

    8.4. Market Attractiveness Analysis By Distribution Channel

9. Global Market Analysis 2018-2022 and Forecast 2023-2033, by Region

    9.1. Introduction

    9.2. Historical Market Size (US$ Mn) Analysis By Region, 2018-2022

    9.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2023-2033

        9.3.1. North America

        9.3.2. Latin America

        9.3.3. Europe

        9.3.4. Asia Pacific

        9.3.5. Middle East and Africa (MEA)

    9.4. Market Attractiveness Analysis By Region

10. North America Market Analysis 2018-2022 and Forecast 2023-2033

    10.1. Introduction

    10.2. Pricing Analysis

    10.3. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022

    10.4. Market Size (US$ Mn) Forecast By Market Taxonomy, 2023-2033

        10.4.1. By Country

            10.4.1.1. U.S.

            10.4.1.2. Canada

        10.4.2. By Disorder

        10.4.3. By Distribution Channel

        10.4.4. By Treatment

    10.5. Market Attractiveness Analysis

        10.5.1. By Country

        10.5.2. By Disorder

        10.5.3. By Distribution Channel

        10.5.4. By Treatment

11. Latin America Market Analysis 2018-2022 and Forecast 2023-2033

    11.1. Introduction

    11.2. Pricing Analysis

    11.3. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022

    11.4. Market Size (US$ Mn) Forecast By Market Taxonomy, 2023-2033

        11.4.1. By Country

            11.4.1.1. Brazil

            11.4.1.2. Mexico

            11.4.1.3. Rest of Latin America

        11.4.2. By Disorder

        11.4.3. By Distribution Channel

        11.4.4. By Treatment

    11.5. Market Attractiveness Analysis

        11.5.1. By Country

        11.5.2. By Disorder

        11.5.3. By Distribution Channel

        11.5.4. By Treatment

12. Europe Market Analysis 2018-2022 and Forecast 2023-2033

    12.1. Introduction

    12.2. Pricing Analysis

    12.3. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022

    12.4. Market Size (US$ Mn) Forecast By Market Taxonomy, 2023-2033

        12.4.1. By Country

            12.4.1.1. Germany

            12.4.1.2. France

            12.4.1.3. Italy

            12.4.1.4. Spain

            12.4.1.5. U.K.

            12.4.1.6. Russia

            12.4.1.7. Rest of Europe

        12.4.2. By Disorder

        12.4.3. By Distribution Channel

        12.4.4. By Treatment

    12.5. Market Attractiveness Analysis

        12.5.1. By Country

        12.5.2. By Disorder

        12.5.3. By Distribution Channel

        12.5.4. By Treatment

13. Asia Pacific Market Analysis 2018-2022 and Forecast 2023-2033

    13.1. Introduction

    13.2. Pricing Analysis

    13.3. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022

    13.4. Market Size (US$ Mn) Forecast By Market Taxonomy, 2023-2033

        13.4.1. By Country

            13.4.1.1. China

            13.4.1.2. Japan

            13.4.1.3. India

            13.4.1.4. Australia & New Zealand

            13.4.1.5. Rest of Asia Pacific

        13.4.2. By Disorder

        13.4.3. By Distribution Channel

        13.4.4. By Treatment

    13.5. Market Attractiveness Analysis

        13.5.1. By Country

        13.5.2. By Disorder

        13.5.3. By Distribution Channel

        13.5.4. By Treatment

14. Middle East and Africa Market Analysis 2018-2022 and Forecast 2023-2033

    14.1. Introduction

    14.2. Pricing Analysis

    14.3. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022

    14.4. Market Size (US$ Mn) Forecast By Market Taxonomy, 2023-2033

        14.4.1. By Country

            14.4.1.1. GCC Countries

            14.4.1.2. South Africa

            14.4.1.3. Rest of Middle East and Africa

        14.4.2. By Disorder

        14.4.3. By Distribution Channel

        14.4.4. By Treatment

    14.5. Market Attractiveness Analysis

        14.5.1. By Country

        14.5.2. By Disorder

        14.5.3. By Distribution Channel

        14.5.4. By Treatment

15. Market Structure Analysis

    15.1. Market Analysis by Tier of Companies

    15.2. Market Concentration

    15.3. Market Share Analysis of Top Players

    15.4. Market Presence Analysis

        15.4.1. By Regional footprint of Players

        15.4.2. Disorder footprint by Players

        15.4.3. Channel footprint by Players

16. Competition Analysis

    16.1. Competition Dashboard

    16.2. Competition Benchmarking

    16.3. Competition Deep Dive (Indicative List)

        16.3.1. Johnson & Johnson (Janssen Global Services, LLC)

            16.3.1.1. Overview

            16.3.1.2. Disorder Portfolio

            16.3.1.3. Sales Footprint

            16.3.1.4. Strategy Overview

        16.3.2. Boehringer Ingelheim GmbH

            16.3.2.1. Overview

            16.3.2.2. Disorder Portfolio

            16.3.2.3. Sales Footprint

            16.3.2.4. Strategy Overview

        16.3.3. NeuroMetrix, Inc

            16.3.3.1. Overview

            16.3.3.2. Disorder Portfolio

            16.3.3.3. Sales Footprint

            16.3.3.4. Strategy Overview

        16.3.4. Eli Lilly and Company

            16.3.4.1. Overview

            16.3.4.2. Disorder Portfolio

            16.3.4.3. Sales Footprint

            16.3.4.4. Strategy Overview

        16.3.5. GlaxoSmithKline plc

            16.3.5.1. Overview

            16.3.5.2. Disorder Portfolio

            16.3.5.3. Sales Footprint

            16.3.5.4. Strategy Overview

        16.3.6. Lupin Limited

            16.3.6.1. Overview

            16.3.6.2. Disorder Portfolio

            16.3.6.3. Sales Footprint

            16.3.6.4. Strategy Overview

        16.3.7. Pfizer Inc

            16.3.7.1. Overview

            16.3.7.2. Disorder Portfolio

            16.3.7.3. Sales Footprint

            16.3.7.4. Strategy Overview

        16.3.8. Astellas Pharma Inc

            16.3.8.1. Overview

            16.3.8.2. Disorder Portfolio

            16.3.8.3. Sales Footprint

            16.3.8.4. Strategy Overview

        16.3.9. Glenmark Pharmaceuticals Ltd

            16.3.9.1. Overview

            16.3.9.2. Disorder Portfolio

            16.3.9.3. Sales Footprint

            16.3.9.4. Strategy Overview

        16.3.10. Arbor Pharmaceuticals, LLC

            16.3.10.1. Overview

            16.3.10.2. Disorder Portfolio

            16.3.10.3. Sales Footprint

            16.3.10.4. Strategy Overview

        16.3.11. Depomed, Inc

            16.3.11.1. Overview

            16.3.11.2. Disorder Portfolio

            16.3.11.3. Sales Footprint

            16.3.11.4. Strategy Overview

        16.3.12. Other Prominent Players

            16.3.12.1. Overview

            16.3.12.2. Disorder Portfolio

            16.3.12.3. Sales Footprint

            16.3.12.4. Strategy Overview

17. Assumptions and Acronyms Used

18. Research Methodology

Don't Need a Global Report?

save 40%! on Country & Region specific reports

List Of Table

Table 01: Global Market Value (US$ Mn) Analysis, by Disorder, 2018 - 2022

Table 02: Global Market Value (US$ Mn) Analysis, by Disorder, 2023 - 2033

Table 03: Global Market Value (US$ Mn) Opportunity Analysis, by Disorder, 2018 - 2022

Table 04: Global Market Value (US$ Mn) Opportunity Analysis, by Disorder, 2023 - 2033

Table 05: Global Market Value (US$ Mn) Analysis, by Treatment, 2018 - 2022

Table 06: Global Market Value (US$ Mn) Analysis, by Treatment, 2023 - 2033

Table 07: Global Market Value (US$ Mn) Opportunity Analysis, by Treatment, 2018 - 2022

Table 08: Global Market Value (US$ Mn) Opportunity Analysis, by Treatment, 2023 - 2033

Table 09: Global Market Value (US$ Mn) Analysis, by Distribution Channel, 2018 - 2022

Table 10: Global Market Value (US$ Mn) Analysis, by Distribution Channel, 2023 - 2033

Table 11: Global Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2018 - 2022

Table 12: Global Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2023 - 2033

Table 13: Global Market Value (US$ Mn) Analysis, by Region, 2018 - 2022

Table 14: Global Market Value (US$ Mn) Analysis, by Region, 2023 - 2033

Table 15: Global Market Value (US$ Mn) Opportunity Analysis, by Region, 2018 - 2022

Table 16: Global Market Value (US$ Mn) Opportunity Analysis, by Region, 2023 - 2033

Table 17: North America Market Value (US$ Mn) Analysis, by Region, 2018 - 2022

Table 18: North America Market Value (US$ Mn) Analysis, by Region, 2023 - 2033

Table 19: North America Market Value (US$ Mn) Opportunity Analysis, by Region, 2018 - 2022

Table 20: North America Market Value (US$ Mn) Opportunity Analysis, by Region, 2023 - 2033

Table 21: North America Market Value (US$ Mn) Analysis, by Disorder, 2018 - 2022

Table 22: North America Market Value (US$ Mn) Analysis, by Disorder, 2023 - 2033

Table 23: North America Market Value (US$ Mn) Opportunity Analysis, by Disorder, 2018 - 2022

Table 24: North America Market Value (US$ Mn) Opportunity Analysis, by Disorder, 2023 - 2033

Table 25: North America Market Value (US$ Mn) Analysis, by Treatment, 2018 - 2022

Table 26: North America Market Value (US$ Mn) Analysis, by Treatment, 2023 - 2033

Table 27: North America Market Value (US$ Mn) Opportunity Analysis, by Treatment, 2018 - 2022

Table 28: North America Market Value (US$ Mn) Opportunity Analysis, by Treatment, 2023 - 2033

Table 29: North America Market Value (US$ Mn) Analysis, by Distribution Channel, 2018 - 2022

Table 30: North America Market Value (US$ Mn) Analysis, by Distribution Channel, 2023 - 2033

Table 31: North America Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2018 - 2022

Table 32: North America Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2023 - 2033

Table 33: Latin America Market Value (US$ Mn) Analysis, by Region, 2018 - 2022

Table 34: Latin America Market Value (US$ Mn) Analysis, by Region, 2023 - 2033

Table 35: Latin America Market Value (US$ Mn) Opportunity Analysis, by Region, 2018 - 2022

Table 36: Latin America Market Value (US$ Mn) Opportunity Analysis, by Region, 2023 - 2033

Table 37: Latin America Market Value (US$ Mn) Analysis, by Disorder, 2018 - 2022

Table 38: Latin America Market Value (US$ Mn) Analysis, by Disorder, 2023 - 2033

Table 39: Latin America Market Value (US$ Mn) Opportunity Analysis, by Disorder, 2018 - 2022

Table 40: Latin America Market Value (US$ Mn) Opportunity Analysis, by Disorder, 2023 - 2033

Table 41: Latin America Market Value (US$ Mn) Analysis, by Treatment, 2018 - 2022

Table 42: Latin America Market Value (US$ Mn) Analysis, by Treatment, 2023 - 2033

Table 43: Latin America Market Value (US$ Mn) Opportunity Analysis, by Treatment, 2018 - 2022

Table 44: Latin America Market Value (US$ Mn) Opportunity Analysis, by Treatment, 2023 - 2033

Table 45: Latin America Market Value (US$ Mn) Analysis, by Distribution Channel, 2018 - 2022

Table 46: Latin America Market Value (US$ Mn) Analysis, by Distribution Channel, 2023 - 2033

Table 47: Latin America Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2018 - 2022

Table 48: Latin America Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2023 - 2033

Table 49: Europe Market Value (US$ Mn) Analysis, by Region, 2018 - 2022

Table 50: Europe Market Value (US$ Mn) Analysis, by Region, 2023 - 2033

Table 51: Europe Market Value (US$ Mn) Opportunity Analysis, by Region, 2018 - 2022

Table 52: Europe Market Value (US$ Mn) Opportunity Analysis, by Region, 2023 - 2033

Table 53: Europe Market Value (US$ Mn) Analysis, by Disorder, 2018 - 2022

Table 54: Europe Market Value (US$ Mn) Analysis, by Disorder, 2023 - 2033

Table 55: Europe Market Value (US$ Mn) Opportunity Analysis, by Disorder, 2018 - 2022

Table 56: Europe Market Value (US$ Mn) Opportunity Analysis, by Disorder, 2023 - 2033

Table 57: Europe Market Value (US$ Mn) Analysis, by Treatment, 2018 - 2022

Table 58: Europe Market Value (US$ Mn) Analysis, by Treatment, 2023 - 2033

Table 59: Europe Market Value (US$ Mn) Opportunity Analysis, by Treatment, 2018 - 2022

Table 60: Europe Market Value (US$ Mn) Opportunity Analysis, by Treatment, 2023 - 2033

Table 61: Europe Market Value (US$ Mn) Analysis, by Distribution Channel, 2018 - 2022

Table 62: Europe Market Value (US$ Mn) Analysis, by Distribution Channel, 2023 - 2033

Table 63: Europe Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2018 - 2022

Table 64: Europe Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2023 - 2033

Table 65: Asia Pacific Market Value (US$ Mn) Analysis, by Region, 2018 - 2022

Table 66: Asia Pacific Market Value (US$ Mn) Analysis, by Region, 2023 - 2033

Table 67: Asia Pacific Market Value (US$ Mn) Opportunity Analysis, by Region, 2018 - 2022

Table 68: Asia Pacific Market Value (US$ Mn) Opportunity Analysis, by Region, 2023 - 2033

Table 69: Asia Pacific Market Value (US$ Mn) Analysis, by Disorder, 2018 - 2022

Table 70: Asia Pacific Market Value (US$ Mn) Analysis, by Disorder, 2023 - 2033

Table 71: Asia Pacific Market Value (US$ Mn) Opportunity Analysis, by Disorder, 2018 - 2022

Table 72: Asia Pacific Market Value (US$ Mn) Opportunity Analysis, by Disorder, 2023 - 2033

Table 73: Asia Pacific Market Value (US$ Mn) Analysis, by Treatment, 2018 - 2022

Table 74: Asia Pacific Market Value (US$ Mn) Analysis, by Treatment, 2023 - 2033

Table 75: Asia Pacific Market Value (US$ Mn) Opportunity Analysis, by Treatment, 2018 - 2022

Table 76: Asia Pacific Market Value (US$ Mn) Opportunity Analysis, by Treatment, 2023 - 2033

Table 77: Asia Pacific Market Value (US$ Mn) Analysis, by Distribution Channel, 2018 - 2022

Table 78: Asia Pacific Market Value (US$ Mn) Analysis, by Distribution Channel, 2023 - 2033

Table 79: Asia Pacific Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2018 - 2022

Table 80: Asia Pacific Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2023 - 2033

Table 81: MEA Market Value (US$ Mn) Analysis, by Region, 2018 - 2022

Table 82: MEA Market Value (US$ Mn) Analysis, by Region, 2023 - 2033

Table 83: MEA Market Value (US$ Mn) Opportunity Analysis, by Region, 2018 - 2022

Table 84: MEA Market Value (US$ Mn) Opportunity Analysis, by Region, 2023 - 2033

Table 85: MEA Market Value (US$ Mn) Analysis, by Disorder, 2018 - 2022

Table 86: MEA Market Value (US$ Mn) Analysis, by Disorder, 2023 - 2033

Table 87: MEA Market Value (US$ Mn) Opportunity Analysis, by Disorder, 2018 - 2022

Table 88: MEA Market Value (US$ Mn) Opportunity Analysis, by Disorder, 2023 - 2033

Table 89: MEA Market Value (US$ Mn) Analysis, by Treatment, 2018 - 2022

Table 90: MEA Market Value (US$ Mn) Analysis, by Treatment, 2023 - 2033

Table 91: MEA Market Value (US$ Mn) Opportunity Analysis, by Treatment, 2018 - 2022

Table 92: MEA Market Value (US$ Mn) Opportunity Analysis, by Treatment, 2023 - 2033

Table 93: MEA Market Value (US$ Mn) Analysis, by Distribution Channel, 2018 - 2022

Table 94: MEA Market Value (US$ Mn) Analysis, by Distribution Channel, 2023 - 2033

Table 95: MEA Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2018 - 2022

Table 96: MEA Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2023 - 2033

More Insights, Lesser Cost (-50% off)

Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR

List Of Figures

Figure 01: Global Market Value (US$ Mn) Historical Analysis, 2018-2022

Figure 02: Global Market Value (US$ Mn) Forecast and Analysis, 2023-2033

Figure 03: Global Market Value Y-o-Y Growth and Forecast, 2018-2033

Figure 04: Global Market Incremental $ Opportunity, 2023-2033

Figure 05: Global Market Share and BPS Analysis by Disorder, 2023 & 2033

Figure 06: Global Market Y-o-Y Growth Projections by Disorder, 2023-2033

Figure 07: Global Market Attractiveness Analysis by Disorder, 2023-2033

Figure 08: Global Market Value (US$ Mn) and Forecast by Peripheral Neuropathy, 2018 - 2033

Figure 09: Global Market Incremental $ Opportunity by Peripheral Neuropathy, 2023-2033

Figure 10: Global Market Value (US$ Mn) and Forecast by Autonomic Neuropathy, 2018 - 2033

Figure 11: Global Market Incremental $ Opportunity by Autonomic Neuropathy, 2023-2033

Figure 12: Global Market Value (US$ Mn) and Forecast by Proximal Neuropathy, 2018 - 2033

Figure 13: Global Market Incremental $ Opportunity by Proximal Neuropathy, 2023-2033

Figure 14: Global Market Value (US$ Mn) and Forecast by Focal Neuropathy, 2018 - 2033

Figure 15: Global Market Incremental $ Opportunity by Focal Neuropathy, 2023-2033

Figure 16: Global Market Share and BPS Analysis by Treatment, 2023 & 2033

Figure 17: Global Market Y-o-Y Growth Projections by Treatment, 2023-2033

Figure 18: Global Market Attractiveness Analysis by Treatment, 2023-2033

Figure 19: Global Market Share and BPS Analysis by Drug, 2023 & 2033

Figure 20: Global Market Y-o-Y Growth Projections by Drug, 2023-2033

Figure 21: Global Market Value (US$ Mn) and Forecast by Drug, 2018 - 2033

Figure 22: Global Market Incremental $ Opportunity by Drug, 2023-2033

Figure 23: Global Market Share and BPS Analysis by Radiotherapy, 2023 & 2033

Figure 24: Global Market Y-o-Y Growth Projections by Radiotherapy, 2023-2033

Figure 25: Global Market Value (US$ Mn) and Forecast by Radiotherapy, 2018 - 2033

Figure 26: Global Market Incremental $ Opportunity by Radiotherapy, 2023-2033

Figure 27: Global Market Share and BPS Analysis by Physiotherapy, 2023 & 2033

Figure 28: Global Market Y-o-Y Growth Projections by Physiotherapy, 2023-2033

Figure 29: Global Market Share and BPS Analysis by Region, 2023 & 2033

Figure 30: Global Market Y-o-Y Growth Projections by Region, 2023-2033

Figure 31: Global Market Attractiveness Analysis by Region, 2023-2033

Figure 32: North America Market Share and BPS Analysis by Country, 2023 & 2033

Figure 33: North America Market Y-o-Y Growth Projections by Country, 2023-2033

Figure 34: North America Market Attractiveness Analysis by Country, 2023-2033

Figure 35: North America Market Value (US$ Mn) Historical Analysis, 2018-2022

Figure 36: North America Market Value (US$ Mn) Forecast and Analysis, 2023-2033

Figure 37: North America Market Value Y-o-Y Growth and Forecast, 2018-2033

Figure 38: North America Market Incremental $ Opportunity, 2023-2033

Figure 39: North America Market Share and BPS Analysis by Disorder, 2023 & 2033

Figure 40: North America Market Y-o-Y Growth Projections by Disorder, 2023-2033

Figure 41: North America Market Attractiveness Analysis by Disorder, 2023-2033

Figure 42: North America Market Share and BPS Analysis by Treatment, 2023 & 2033

Figure 43: North America Market Y-o-Y Growth Projections by Treatment, 2023-2033

Figure 44: North America Market Attractiveness Analysis by Treatment, 2023-2033

Figure 45: North America Market Value (US$ Mn) and Forecast by Drug, 2018 - 2033

Figure 46: North America Market Incremental $ Opportunity by Drug, 2023-2033

Figure 47: North America Market Value (US$ Mn) and Forecast by Radiotherapy, 2018 - 2033

Figure 48: North America Market Incremental $ Opportunity by Radiotherapy, 2023-2033

Figure 49: Latin America Market Share and BPS Analysis by Country, 2023 & 2033

Figure 50: Latin America Market Y-o-Y Growth Projections by Country, 2023-2033

Figure 51: Latin America Market Attractiveness Analysis by Country, 2023-2033

Figure 52: Latin America Market Value (US$ Mn) Historical Analysis, 2018-2022

Figure 53: Latin America Market Value (US$ Mn) Forecast and Analysis, 2023-2033

Figure 54: Latin America Market Value Y-o-Y Growth and Forecast, 2018-2033

Figure 55: Latin America Market Incremental $ Opportunity, 2023-2033

Figure 56: Latin America Market Share and BPS Analysis by Disorder, 2023 & 2033

Figure 57: Latin America Market Y-o-Y Growth Projections by Disorder, 2023-2033

Figure 58: Latin America Market Attractiveness Analysis by Disorder, 2023-2033

Figure 59: Latin America Market Share and BPS Analysis by Treatment, 2023 & 2033

Figure 60: Latin America Market Y-o-Y Growth Projections by Treatment, 2023-2033

Figure 61: Latin America Market Attractiveness Analysis by Treatment, 2023-2033

Figure 62: Latin America Market Value (US$ Mn) and Forecast by Drug, 2018 - 2033

Figure 63: Latin America Market Incremental $ Opportunity by Drug, 2023-2033

Figure 64: Latin America Market Value (US$ Mn) and Forecast by Radiotherapy, 2018 - 2033

Figure 65: Latin America Market Incremental $ Opportunity by Radiotherapy, 2023-2033

Figure 66: Europe Market Share and BPS Analysis by Country, 2023 & 2033

Figure 67: Europe Market Y-o-Y Growth Projections by Country, 2023-2033

Figure 68: Europe Market Attractiveness Analysis by Country, 2023-2033

Figure 69: Europe Market Value (US$ Mn) Historical Analysis, 2018-2022

Figure 70: Europe Market Value (US$ Mn) Forecast and Analysis, 2023-2033

Figure 71: Europe Market Value Y-o-Y Growth and Forecast, 2018-2033

Figure 72: Europe Market Incremental $ Opportunity, 2023-2033

Figure 73: Europe Market Share and BPS Analysis by Disorder, 2023 & 2033

Figure 74: Europe Market Y-o-Y Growth Projections by Disorder, 2023-2033

Figure 75: Europe Market Attractiveness Analysis by Disorder, 2023-2033

Figure 76: Europe Market Share and BPS Analysis by Treatment, 2023 & 2033

Figure 77: Europe Market Y-o-Y Growth Projections by Treatment, 2023-2033

Figure 78: Europe Market Attractiveness Analysis by Treatment, 2023-2033

Figure 79: Europe Market Value (US$ Mn) and Forecast by Drug, 2018 - 2033

Figure 80: Europe Market Incremental $ Opportunity by Drug, 2023-2033

Figure 81: Europe Market Value (US$ Mn) and Forecast by Radiotherapy, 2018 - 2033

Figure 82: Europe Market Incremental $ Opportunity by Radiotherapy, 2023-2033

Figure 83: Asia Pacific Market Share and BPS Analysis by Country, 2023 & 2033

Figure 84: Asia Pacific Market Y-o-Y Growth Projections by Country, 2023-2033

Figure 85: Asia Pacific Market Attractiveness Analysis by Country, 2023-2033

Figure 86: Asia Pacific Market Value (US$ Mn) Historical Analysis, 2018-2022

Figure 87: Asia Pacific Market Value (US$ Mn) Forecast and Analysis, 2023-2033

Figure 88: Asia Pacific Market Value Y-o-Y Growth and Forecast, 2018-2033

Figure 89: Asia Pacific Market Incremental $ Opportunity, 2023-2033

Figure 90: Asia Pacific Market Share and BPS Analysis by Disorder, 2023 & 2033

Figure 91: Asia Pacific Market Y-o-Y Growth Projections by Disorder, 2023-2033

Figure 92: Asia Pacific Market Attractiveness Analysis by Disorder, 2023-2033

Figure 93: Asia Pacific Market Share and BPS Analysis by Treatment, 2023 & 2033

Figure 94: Asia Pacific Market Y-o-Y Growth Projections by Treatment, 2023-2033

Figure 95: Asia Pacific Market Attractiveness Analysis by Treatment, 2023-2033

Figure 96: Asia Pacific Market Value (US$ Mn) and Forecast by Drug, 2018 - 2033

Figure 97: Asia Pacific Market Incremental $ Opportunity by Drug, 2023-2033

Figure 98: Asia Pacific Market Value (US$ Mn) and Forecast by Radiotherapy, 2018 - 2033

Figure 99: Asia Pacific Market Incremental $ Opportunity by Radiotherapy, 2023-2033

Figure 100: MEA Market Share and BPS Analysis by Country, 2023 & 2033

Figure 101: MEA Market Y-o-Y Growth Projections by Country, 2023-2033

Figure 102: MEA Market Attractiveness Analysis by Country, 2023-2033

Figure 103: MEA Market Value (US$ Mn) Historical Analysis, 2018-2022

Figure 104: MEA Market Value (US$ Mn) Forecast and Analysis, 2023-2033

Figure 105: MEA Market Value Y-o-Y Growth and Forecast, 2018-2033

Figure 106: MEA Market Incremental $ Opportunity, 2023-2033

Figure 107: MEA Market Share and BPS Analysis by Disorder, 2023 & 2033

Figure 108: MEA Market Y-o-Y Growth Projections by Disorder, 2023-2033

Figure 109: MEA Market Attractiveness Analysis by Disorder, 2023-2033

Figure 110: MEA Market Share and BPS Analysis by Treatment, 2023 & 2033

Figure 111: MEA Market Y-o-Y Growth Projections by Treatment, 2023-2033

Figure 112: MEA Market Attractiveness Analysis by Treatment, 2023-2033

Figure 113: MEA Market Value (US$ Mn) and Forecast by Drug, 2018 - 2033

Figure 114: MEA Market Incremental $ Opportunity by Drug, 2023-2033

Figure 115: MEA Market Value (US$ Mn) and Forecast by Radiotherapy, 2018 - 2033

Figure 116: MEA Market Incremental $ Opportunity by Radiotherapy, 2023-2033

Know thy Competitors

Competitive landscape highlights only certain players
Complete list available upon request

- FAQs -

What is the current size of the diabetic neuropathy market?

The global diabetic neuropathy market is valued at US$ 4.2 billion in 2023.

How big will the market be by the end of the forecast period?

Demand for diabetic neuropathy treatment is set to amass a revenue of US$ 8 billion by 2033-end.

At what CAGR will the market for diabetic neuropathy progress?

From 2023 to 2033, diabetic neuropathy demand is set to rise at 6.6% CAGR.

What percentage of diabetics have neuropathy?

Nearly 50% of all diabetic patients suffer from neuropathy.

Which diabetic neuropathy disorder is the most common?

Peripheral diabetic neuropathy is the most common type at present.

Diabetic Neuropathy Market

Schedule a Call